|
| |
SYNT:EMSynt:em is a private French biopharmaceutical company that is focused on the discovery and development of novel drugs that address unmet medical needs in cancer, pain management and diseases of the Central Nervous System.
Synt:em’s strategy is to take advantage of its complementary and proprietary technology platforms Pep:trans™ and Acti:map™ to develop an internal pipeline of drug candidates for the treatment of CNS disorders. In addition, Synt:em will continue establishing strong partnerships with Pharma and Biotech companies based on its Pep:trans™ and Acti:map™ technologies.
Pep:trans™ is a unique way to modify the pharmacological behaviour of compounds ranging from small molecules to peptides or proteins, by helping them to reach their target across complex biological membranes. With Pep:trans™, Synt:em is able to address the problem of delivering therapeutic molecules to the brain through the Blood Brain Barrier. In addition, the technology is used to improve the uptake of therapeutics into cells so that they are able to interact optimally with intracellular targets.
| Contact Details: |
| Parc ScientifiqueGeorges Besse |
| Nîmes |
| Cedex 1 |
| 30035 |
| France |
| Tel: | 33 (0)466 048 666 |
| Fax: | 33 (0)466 048 667 |
| Email: | syntem@syntem.com |
| WWW: | www.syntem.com/
|
| |
Recent Publications by SYNT:EM: |  |
Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain delivery.
BACKGROUND: SynB family peptides conjugated to several drugs have been... | 17th March, 2007
| Synt:em,
| Chemotherapy. 2007;53(1):73-6. Epub 2007 Jan 3.
DOI Direct Link |
Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 1. Anti-infective drugs.
Except for a few well-documented CNS therapeutics, quantitative data on... | 17th March, 2007
| Synt:em,
| Chemotherapy. 2007;53(1):70-2. Epub 2007 Jan 3.
DOI Direct Link |
Improved brain uptake and pharmacological activity profile of morphine-6-glucuronide using a peptide vector-mediated strategy.
Morphine-6-glucuronide (M6G), an active metabolite of morphine, has been... | 6th July, 2005
| Synt:em, Parc Scientifique Georges Besse, Nimes, France.
| J Pharmacol Exp Ther. 2005 May;313(2):712-9. Epub 2005 Jan 12.
DOI Direct Link |
Peptide-vector strategy bypasses P-glycoprotein efflux, and enhances brain transport and solubility of paclitaxel.
We present the results obtained with paclitaxel coupled to a... | 29th June, 2005
| Synt:em, Institut de Genetique Moleculaire de Montpellier, CNRS UMR 5535,
| Anticancer Drugs. 2004 Nov;15(10):947-54.
|
The use of cell-penetrating peptides for drug delivery.
In the past decade, several peptides that can translocate cell membranes... | 22nd December, 2004
| Synt:em, Parc Scientifique Georges Besse, 30000 Nimes, France.
| Drug Discov Today. 2004 Dec 1;9(23):1012-9.
DOI Direct Link |
→View more SYNT:EM research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 236 times since April 2007, the link to the organisation's website has been followed 33 times Recent Search Terms used to find this page: synt:em | synt em patent pain | synt em patent pain | syntem | syntem | syntem | Syntem address | . Search for more companies in Nîmes Search for more companies in Cedex 1 This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for SYNT:EM |
